Capecitabine in gastric cancer

Drugs of Today

Volumn 44, Issue 8, 2008, Pages 629-640

  Okines, Alicia ^a   Chau, Ian ^a,b   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ENZYME INHIBITOR; EPIRUBICIN; FLUOROURACIL; FLUOROURACIL PLUS FOLINATE CALCIUM; FOLINIC ACID; GIMERACIL; IRINOTECAN; MATUZUMAB; MITOMYCIN C; ORZEL; OTERACIL; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TEGAFUR; UFT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ASTHENIA; BONE MARROW SUPPRESSION; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; REVIEW; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; VERTIGO; VOMITING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PROTEIN BINDING; STOMACH NEOPLASMS;

EID: 56049089012     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.8.1244748     Document Type: Review

References (71)

1. Parkin, D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2(9): 533-43.
2. Pyrhönen, S., Kuitunen, T., Nyandoto, P., Kouri, M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71 (3): 587-91.
3. Murad, A.M., Santiago, F.F., Petroianu, A., Rocha, P.R., Rodrigues, M.A., Rausch, M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72(1): 37-41.
4. Wagner, A.D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., Fleig, W.E. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24(18): 2903-9.
5. Cunningham, D., Allum, W.H., Stenning, S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1): 11-20.
6. Fiorica, F., Cartei, F., Enea, M. et al. The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. Cancer Treat Rev 2007, 33(8): 729-40.
7. Wu, A.W., Xu, G.W., Wang, H.Y., Ji, J.F., Tang, J.L Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev 2007, Apr 18 (2): CD005047.
8. Cunningham, D., Starling, N., Rao, S. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1): 36-46.
9. Kang, Y., Shin, D., Chen, J. et al. Capecitabine/cisplatin vs. continuous infusion of 5FU/cisplatin as firstline therapy in patients (pts) with advanced gastric cancer (AGC): A randomised phase III trial. Eur J Cancer Suppl 2007, 5(4): Abst 3501.
10. Reigner, B., Blesch, K., Weidekamm, E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001, 40(2): 85-104.
11. Budman, D.R., Meropol, N.J., Reigner, B. et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998, 16(5): 1795-802.
12. Reigner, B., Verweij, J., Dirix, L. et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998, 4(4): 941-8.
13. Ishitsuka, H. Capecitabine: Preclinical pharmacology studies. Invest New Drugs 2000, 18(4): 343-54.
14. Miwa, M., Ura, M., Nishida, M. et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34(8): 1274-81.
15. Nishina, T., Hyodo, I., Miyaike, J., Inaba, T., Suzuki, S., Shiratori, Y. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridine. Eur J Cancer 2004, 40(10): 1566-71.
16. Wei, X., McLeod, H.L., McMurrough, J., Gonzalez, F.J., Fernandez-Salguero, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996, 98(3): 610-5.
17. Gamelin, E., Boisdron-Celle, M., Morel, A. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines]. Therapie 2007, 62(2): 99-103.
18. Judson, I.R., Beale, P.J., Trigo, J.M. et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 1999, 17(1): 49-56.
19. Poole, C., Gardiner, J., Twelves, C. et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002, 49(3): 225-34.
20. Mackean, M., Planting, A., Twelves, C. et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998, 16(9): 2977-85.
21. Cassidy, J., Dirix, L., Bissett, D. et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998, 4(11): 2755-61.
22. Delord, J.P., Pierga, J.Y., Dieras, V. et al. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 2005, 92(5): 820-6.
23. Villalona-Calero, M.A., Weiss, G.R., Burris, H.A. et al. Phase I and pharmacokinetic study of the oral fluo ropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 1999, 17(6): 1915-25.
24. Pronk, L.C., Vasey, P., Sparreboom, A. et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000, 83(1): 22-9.
25. Ramanathan, R.K., Ramalingam, S., Egorin, M.J. et al. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2005, 55(4): 354-60.
26. Evans, D., Miner, T., Iannitti, D. et al. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: A phase II study. Cancer Invest 2007, 25(6): 445-8.
27. Fakih, M.G., Creaven, P.J., Ramnath, N. et al. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res 2005, 11(16): 5942-9.
28. Evans, D., Miner, T., Akerman, P. et al. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol 2007, 30(4): 346-9.
29. Evans, T.R., Pentheroudakis, G., Paul, J. et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 2002, 13(9): 1469-78.
30. Dupont, J., Jensen, H.A., Jensen, B.V., Pfeiffer, P. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Acta Oncol 2007, 46(3): 330-5.
31. Rao, S., Starling, N., Benson, M. et al. Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. J Clin Oncol 2005, 23(165, Pt. I): Abst 4028.
32. Koizumi, W., Saigenji, K., Ujiie, S. et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003, 64(3): 232-6.
33. Sakamoto, J., Chin, K., Kondo, K. et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 2006, 17(2): 231-6.
34. Hong, Y.S., Song, S.Y., Lee, S.I. et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004, 15(9): 1344-7.
35. Baek, J.H., Kim, J.G., Jeon, S.B. et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2006, 94(10): 1407-11.
36. Kim, T.W., Kang, Y.K., Ahn, J.H. et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002, 13(12): 1893-8.
37. Kang, H.J., Chang, H.M., Kim, T.W. et al. A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer 2008, 98(2): 316-22.
38. Park, Y.H., Ryoo, B.Y., Choi, S.J., Kim, HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004, 90(7): 1329-33.
39. Park, Y.H., Kim, B.S., Ryoo, B.Y., Yang, S.H. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 2006, 94(7): 959-63.
40. Cho, E.K., Lee, W.K., Im, S.A. et al. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 2005, 68(4-6): 333-40.
41. Kang, Y., Kim, T., Chang, H. et al. A phase I / II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer. Gastrointest Cancers Symp 2004, Abst 73.
42. Shah, M.A., Ramanathan, R.K., Ilson, D.H. et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24(33): 5201-6.
43. Fuchs, C.S., Marshall, J., Mitchell, E. et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007, 25(30): 4779-86.
44. Cassidy, J., Clarke, S., Diaz-Rubio, E. et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007, 25(183, Pt. I): Abst 4030.
45. Van Cutsem, E., Michael, M., Berry, S. et al. Preliminary safety and efficacy of bevacizumab with firstline FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: First BEATrial. Gastrointest Cancers Symp 2007, Abst 346.
46. Hochster, H.S., Hart, L.L., Ramanathan, R.K., Hainsworth, J.D., Hedrick, E.E., Childs, B.H. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 2006, 24(185, R. I): Abst 3510.
47. Saltz, L., Clarke, S., Diaz-Rubio, E. et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007, 25(18S, Pt. I.): 4028.
48. Bang, Y., Chung H., Sawaki, A. et al. HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial. J Clin Oncol 2008, 26(Suppl.) Abst 4526.
49. Jansen, E.P., Boot, H., Saunders, M.P. et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 2007, 69(5): 1424-8.
50. Jansen, E.P., Boot, H., Dubbelman, R., Bartelink, H., Cats, A., Verheij, M. Postoperative chemoradiotherapy in gastric cancer - a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer 2007, 97(6): 712-6.
51. Macdonald, J.S., Smalley, S.R., Benedetti, J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345(10): 725-30.
52. Boige, V., Pignon, J., Saint-Aubert, B. et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007, 25(188, Pt. I): Abst 4510.
53. Kang, Y., Kang, W.K., Shin, D.B. et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol 2006, 24(183, Pt. I): Abst LBA4108.
54. Nakajima T, Kinoshita T, Nashimoto A et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007, 94(12): 1468-76.
55. Sakuramoto, S., Sasako, M., Yamaguchi, T. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357(12): 1810-20.
56. Liu, T.S., Wang, Y., Chen, S.Y., Sun, Y.H. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008, March 17: Epub ahead of print.
57. Kim, Y.H., Cheong, S.K., Lee, J.D., Park, J.S., Shin, S.W., Kim, J.S. Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol 1996, 19(2): 212-6.
58. Kim, Y.H., Shin, S.W., Kim, B.S., Park, Y.T., Kim, J.G., Kim, J.S. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. Oncology 1997, 11(9, Suppl. 10): 119-23.
59. Woo, I.S., Moon, D.H., Shim, B.Y. et al. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Jpn J Clin Oncol 2005, 35(1): 13-7.
60. Jeen, Y.T., Yoon, S.Y., Shin, S.W. et al. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 2001, 91(12): 2288-93.
61. Ohtsu, A., Shimada, Y., Shirao, K. et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003, 21(1): 54-9.
62. van Groeningen, C.J., Peters, G.J., Schomagel, J.H. et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000, 18(14:2772-9.
63. Boku, N., Yamamoto, S., Shirao, K. et al. Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 2007, 25(188, Pt. I): Abst LBA4513.
64. Koizumi, W., Narahara, H., Hara, T. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008, 9(3): 215-21.
65. Jin, M., Lu, H., Li, J. et al. Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CD-DP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. J Clin Oncol 2008, 26(Suppl.): Abst 4533.
66. Imamura, H., Ilishi, H., Tsuburaya, A. et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Gastrointest Cancers Symp 2008, Abst 5.
67. Kang, Y., Lee, J., Min, Y. et al. A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. J Clin Oncol 2007, 25(188, Pt. I): Abst 4546.
68. Pfeiffer, P., Mortensen, J.P., Bjerregaard, B. et al. Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006, 42(16): 2738-43.
69. Twelves, C., Gollins, S., Grieve, R., Samuel, L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006, 17(2): 239-45.
70. Borner, M.M., Schoffski, P., de Wit, R. et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002, 38(3): 349-58.
71. Okines, A., McCloud, P., Kang, Y-K., Cunningham, D. Meta-analysis of the REAL-2 and ML17032 trials comparing capecitabine with 5-fluorouracil (S-FU) in advanced oesophago-gastric cancer. Ann Oncol [33rd Eur Soc Med Oncol (ESMO) Congr (Sept 12-18, Stockholm) 2008] 2008, 19(Suppl. 8): Abst 513PD.